2025-09-04 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, broken down into sections with a concluding summary.  The report is in English with numerical data highlighted and followed by brief analysis.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and manufactures medicines and vaccines.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -7.71%
*   **VOO Cumulative Return:** 99.17%
*   **Absolute Divergence (Current):** -111.9%
*   **Relative Divergence:** 0.0

**Analysis:** MRK significantly underperformed the S&P 500 (VOO) over the analyzed period. The cumulative return is substantially negative, and the divergence indicates a severe lag in performance. The relative divergence being at 0.0 means the current divergence is at the lowest end of its historical range.

### 2. Alpha, Beta, and Risk Metrics

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 5.0%    | 58.2%  | -24.0%  | -0.0  | 134.1  |
| 2016-2018  | 43.0%   | 66.4%  | 25.0%   | -0.1  | 182.1  |
| 2017-2019  | 40.0%   | 66.4%  | 11.0%   | 0.3   | 216.7  |
| 2018-2020  | 20.0%   | 66.4%  | 0.0%    | 0.3   | 194.9  |
| 2019-2021  | -1.0%   | 65.6%  | -50.0%  | 0.3   | 191.4  |
| 2020-2022  | 13.0%   | 69.5%  | 11.0%   | 0.3   | 277.1  |
| 2021-2023  | 31.0%   | 69.5%  | 13.0%   | 0.3   | 272.3  |
| 2022-2024  | -7.0%   | 69.5%  | -33.0%  | 0.2   | 248.4  |
| 2023-2025  | -60.0%  | 71.5%  | -111.0% | 0.5   | 211.4  |

**Analysis:**

*   **CAGR:**  Fluctuating CAGR values indicate inconsistent growth over different periods. The most recent period (2023-2025) shows a significant decline.
*   **MDD:** High Maximum Drawdown (MDD) figures suggest significant risk and potential for large losses.
*   **Alpha:** Alpha values are largely negative, especially in recent periods, indicating underperformance relative to the benchmark.
*   **Beta:** Beta values are generally low (around 0.3, although they began at nearly 0), suggesting that MRK's price movements are less sensitive to overall market movements.  However, the Beta increase to 0.5 in the most recent period warrants closer attention. This could suggest that it's starting to react more similarly to the market.
*   **Cap(B):** Market capitalization has fluctuated but shows an overall downward trend, indicating investor sentiment is diminishing.

### 3. Recent Stock Price Movements

*   **Current Price:** 84.645
*   **Last Market Close:** Price: 84.63, Previous Close: 85.48, Change: -0.99
*   **5-day Moving Average:** 84.207
*   **20-day Moving Average:** 83.2453
*   **60-day Moving Average:** 81.8376

**Analysis:** The stock price has recently decreased slightly. The 5-day moving average is above the 20-day and 60-day moving averages, which *could* indicate a short-term upward trend. However, the recent price decrease of -0.99 suggests some downward pressure.

### 4. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3403 (Low Risk)
*   **RSI:** 66.45 (Approaching overbought territory)
*   **PPO:** -0.0415
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** -2.8 (Negative - Short-term decline)
*   **Expected Return (%):** -1304.0%

**Analysis:**

*   **MRI:** The MRI indicates a low-risk environment, but it is at the upper end of "Low Risk", suggesting caution.
*   **RSI:** An RSI of 66.45 is approaching overbought territory, suggesting the stock *may* be due for a pullback.
*   **PPO:** A negative PPO indicates that the short-term moving average is below the long-term moving average, which *could* signal a downward trend.
*   **Hybrid Signal:** The hybrid signal suggests a cautious approach, recommending a partial buy.
*   **Relative Divergence Change:** The negative change in relative divergence confirms a recent short-term decline compared to the benchmark.
*   **Expected Return:** The significantly negative expected return (-1304.0%) is extremely concerning and suggests highly unfavorable long-term prospects based on the model's calculations.

The 'change' of -0.99 from the previous close and the RSI near overbought levels suggest a potential issue of stock volatility and instability, particularly since other indicators are negative.

### 5. Recent News & Significant Events

*   **[2025-09-03]:** Major business developments, regulatory changes, or market events impacting MRK.
*   **[2025-09-01]:** Analysts discussing MRK's recent performance and outlook within industry and global economic contexts.
*   **[2025-09-04]:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **[2025-09-02]:** Market experts highlight both risks and opportunities, advising investors to monitor recent news and company announcements.

**Analysis:**  Recent news points to significant events influencing MRK's stock, including volatility and analyst discussions. This reinforces the need for careful monitoring of company announcements and market trends.

### 6. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2024-08-05 | 2.15 | 16.11 B$  |
| 2025-08-05 | 2.15 | 16.11 B$  |

**Analysis:** The earnings data shows fluctuating EPS and revenue figures. Recent EPS has decreased from 2.15 in 2024-08-05 to 1.76 in 2025-08-05, but the revenue has increased slightly. These changes suggest potential issues with profitability efficiency.

### 7. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|----------------|
| 2025-06-30 | $15.81B  | 77.50%         |
| 2025-03-31 | $15.53B  | 77.98%         |
| 2024-12-31 | $15.62B  | 75.50%         |
| 2024-09-30 | $16.66B  | 75.51%         |
| 2024-06-30 | $16.11B  | 76.76%         |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-06-30 | $48.99B  | 9.04%   |
| 2025-03-31 | $48.34B  | 10.51%  |
| 2024-12-31 | $46.31B  | 8.08%   |
| 2024-09-30 | $44.50B  | 7.09%   |
| 2024-06-30 | $43.58B  | 12.52%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue has fluctuated but remained relatively stable. The profit margin is high, consistently above 75%, indicating strong profitability.
*   **Capital and Profitability:** Equity has generally increased, showing growth in the company's asset base. ROE has fluctuated, with the most recent value lower than previous periods, suggesting a potential decrease in efficiency of equity utilization.

### 8. Overall Summary

Merck & Co Inc (MRK) is currently facing challenges.  It has significantly underperformed the S&P 500, exhibiting negative alpha and a concerning negative expected return. While revenue and profit margins remain strong, recent declines in EPS and ROE raise concerns. The company exhibits low market risk according to MRI, but the recent stock price volatility and the technical indicators (RSI nearing overbought, negative PPO) suggest potential short-term downward pressure. The recent news highlights significant events and analyst scrutiny, emphasizing the need for careful monitoring. Investors should exercise caution and conduct thorough due diligence before making any investment decisions regarding MRK. The high volatility and recent poor performance suggest that this stock may be best suited for experienced investors with a high-risk tolerance and a deep understanding of the pharmaceutical industry.
